These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 2786762)
1. Investigation of immunosuppressive properties of inactivated human immunodeficiency virus and possible neutralization of this effect by some patient sera. Hofmann B; Langhoff E; Lindhardt BO; Odum N; Hyldig-Nielsen JJ; Ryder LP; Platz P; Jakobsen BK; Bendtzen K; Jacobsen N Cell Immunol; 1989 Jul; 121(2):336-48. PubMed ID: 2786762 [TBL] [Abstract][Full Text] [Related]
2. Sera from patients with the acquired immunodeficiency syndrome inhibit production of interleukin-2 by normal lymphocytes. Siegel JP; Djeu JY; Stocks NI; Masur H; Gelmann EP; Quinnan GV J Clin Invest; 1985 Jun; 75(6):1957-64. PubMed ID: 2989337 [TBL] [Abstract][Full Text] [Related]
3. Retrovirus-mediated immunosuppression. I. FeLV-UV and specific FeLV proteins alter T lymphocyte behavior by inducing hyporesponsiveness to lymphokines. Orosz CG; Zinn NE; Olsen RG; Mathes LE J Immunol; 1985 May; 134(5):3396-403. PubMed ID: 2984289 [TBL] [Abstract][Full Text] [Related]
4. HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. Weinhold KJ; Lyerly HK; Stanley SD; Austin AA; Matthews TJ; Bolognesi DP J Immunol; 1989 May; 142(9):3091-7. PubMed ID: 2468713 [TBL] [Abstract][Full Text] [Related]
5. Correlation of the suppressive activity of a biological response modifier on the proliferation of peripheral blood mononuclear cells and the reduction of HIV titer. Vila LM; Ríos-Olivares E; Vila S; Ríos Z; Rivera E; Robles R; Reyes JC; Castillo X Cell Mol Biol (Noisy-le-grand); 1997 Nov; 43(7):981-8. PubMed ID: 9449530 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of interleukin-2-induced T-cell proliferation by sera from patients with the acquired immune deficiency syndrome. Donnelly RP; Tsang KY; Galbraith GM; Wallace JI J Clin Immunol; 1986 Jan; 6(1):92-101. PubMed ID: 3007564 [TBL] [Abstract][Full Text] [Related]
7. Immunosuppressive factor produced by a B cell line derived from an adult T cell leukemia patient. Mori N; Yamashita U; Tanaka Y; Nagata K; Nakata K; Oda S; Eto S Int J Hematol; 1992 Aug; 56(1):29-39. PubMed ID: 1391804 [TBL] [Abstract][Full Text] [Related]
8. Synthetic peptides homologous to HIV transmembrane glycoprotein suppress normal human lymphocyte blastogenic response. Chanh TC; Kennedy RC; Kanda P Cell Immunol; 1988 Jan; 111(1):77-86. PubMed ID: 3257417 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of natural killer cell activities from normal donors and AIDS patients by envelope peptides from human immunodeficiency virus type I. Nair MP; Schwartz SA Cell Mol Biol (Noisy-le-grand); 1997 Nov; 43(7):969-79. PubMed ID: 9449529 [TBL] [Abstract][Full Text] [Related]
12. HIV inhibits the early steps of lymphocyte activation, including initiation of inositol phospholipid metabolism. Hofmann B; Nishanian P; Baldwin RL; Insixiengmay P; Nel A; Fahey JL J Immunol; 1990 Dec; 145(11):3699-705. PubMed ID: 1978848 [TBL] [Abstract][Full Text] [Related]
13. Effects of interleukin 2 and large envelope glycoprotein (gp 120) of human immunodeficiency virus (HIV) on lymphocyte proliferative responses to cytomegalovirus. Krowka J; Stites D; Mills J; Hollander H; McHugh T; Busch M; Wilhelm L; Blackwood L Clin Exp Immunol; 1988 May; 72(2):179-85. PubMed ID: 2842093 [TBL] [Abstract][Full Text] [Related]
14. Interleukin-10 enhances human immunodeficiency virus type 1 expression in a chronically infected promonocytic cell line (U1) by a tumor necrosis factor alpha-independent mechanism. Angel JB; Saget BM; Wang MZ; Wang A; Dinarello CA; Skolnik PR J Interferon Cytokine Res; 1995 Jun; 15(6):575-84. PubMed ID: 7553227 [TBL] [Abstract][Full Text] [Related]
16. A new human retrovirus isolate of West African origin (SBL-6669) and its relationship to HTLV-IV, LAV-II, and HTLV-IIIB. Albert J; Bredberg U; Chiodi F; Böttiger B; Fenyö EM; Norrby E; Biberfeld G AIDS Res Hum Retroviruses; 1987; 3(1):3-10. PubMed ID: 3040053 [TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive and anticancer effect of a mammalian ribonuclease that targets high-affinity interleukin-2-receptors. Yamamura T; Ueda M; Psarras K; Suwa T; Watanaabe Y; Kameyama N; Tanabe M; Imamura H; Kitajima M Eur J Surg; 2002; 168(1):49-54. PubMed ID: 12022372 [TBL] [Abstract][Full Text] [Related]
18. Immunizations of monkeys with synthetic peptides disclose conserved areas on gp120 of human immunodeficiency virus type 1 associated with cross-neutralizing antibodies and T-cell recognition. Vahlne A; Horal P; Eriksson K; Jeansson S; Rymo L; Hedström KG; Czerkinsky C; Holmgren J; Svennerholm B Proc Natl Acad Sci U S A; 1991 Dec; 88(23):10744-8. PubMed ID: 1961741 [TBL] [Abstract][Full Text] [Related]
19. Decreased accessory cell function by human monocytic cells after infection with HIV. Petit AJ; Tersmette M; Terpstra FG; de Goede RE; van Lier RA; Miedema F J Immunol; 1988 Mar; 140(5):1485-9. PubMed ID: 2964477 [TBL] [Abstract][Full Text] [Related]
20. V3 loop of human immunodeficiency virus type 1 suppresses interleukin 2-induced T cell growth. Sakaida H; Murakami T; Kawamata S; Hattori T; Uchiyama T AIDS Res Hum Retroviruses; 1997 Jan; 13(2):151-9. PubMed ID: 9007200 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]